Coherus生物科学 CHRS 深 沪
等待开盘 08-22 09:30:00 美东时间
1.115
+0.045
+4.21%
华盛通- 最 高1.15
- 今 开1.06
- 成交量 93.42万股
- 最 低 1.06
- 昨 收 1.07
- 总市值 1.29亿
- 52周最高 2.43
- 市盈率 静 4.49
- 换手率 0.00%
- 52周最低 0.6603
- 委 比 -50.12%
- 总股本 1.16亿
- 历史最高 38.10
- 量 比 1.52
- 振 幅 8.41%
- 历史最低 0.6603
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Coherus BioSciences Q2 Adj. EPS $(0.34) Misses $(0.28) Estimate, Sales $10.254M Miss $10.946M Estimate
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 22.74 percent. This is a 142.86 percent decrease over losses of $(0.14) per share
08-08 05:16
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
Coherus Oncology announced its second-quarter 2025 financial results will be released after market close on August 7, 2025. A conference call and webcast to discuss the results and provide a business update will begin at 5:00 p.m. EDT on the same day. Conference call dial-in details and webcast links are provided, with a replay available on the company's investor website. Coherus is an oncology company with an approved PD-1 inhibitor, LOQTORZI, g...
07-31 20:45
Top rated and bottom rated stocks according to 3 key drivers of performance – UBS
UBS analysts listed top and bottom-ranked stocks based on a key set of drivers for equities, they named REVS. UBS’s REVS framework consists of elements that are key drivers for equity performance, inc...
07-11 23:33
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
Coherus Oncology, a biopharmaceutical company, has rebranded to emphasize its focus on innovative immuno-oncology therapies. The company is developing a pipeline of combination therapies targeting immune resistance in cancer. Its lead product, LOQTORZI, a PD-1 inhibitor, is approved for nasopharyngeal carcinoma and is being studied for additional indications. Other candidates include CHS-114, a CCR8+ Treg-targeting antibody, and Casdozokitug, an ...
05-30 12:00
Coherus BioSciences Announces Clinical Collaboration With STORM Therapeutics To Evaluate STC-15, METTL3 Inhibitor, In Combination With LOQTORZI, Next-Gen PD-1 Inhibitor, In Phase 1b/2 Study For NSCLC, HNSCC, Melanoma And Endometrial Cancer Treatment
Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. ("STORM") to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI
05-27 20:36
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
Coherus BioSciences collaborates with STORM Therapeutics to evaluate the combination of STC-15, a METTL3 inhibitor, and LOQTORZI, a next-generation PD-1 inhibitor, in a Phase 1b/2 study for treating NSCLC, HNSCC, melanoma, and endometrial cancer. The Phase 1b study assesses safety and efficacy, while the Phase 2 portion expands into these cancers, enrolling up to 188 patients in the U.S. Coherus supplies LOQTORZI, with each company retaining comm...
05-27 12:30
Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Are Reducing Their Forecasts For This Year
The analysts covering Coherus BioSciences, Inc. (NASDAQ:CHRS) delivered a dose ...
05-15 18:56
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers CNS Pharma (NASDAQ:CNSP) shares rose 90.1% to $2.3 during Tuesday's pr...
05-13 20:10
